Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL)1Patients receivingPolivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes, during and after fixed-duration treatment, to those receiving the current standard-of-care, withsuperiorprogression-free survival2Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy ® (polatuzumab vedotin) were presented at the 64th American Society of Hematology (ASH) Annual Meeting& Exposition, 10-13 December. Data from the POLARIX study support the potential benefit of Polivy in combination with MabThera ®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to improve outcomes for people with previously untreated diffuse large B-cell lymphoma (DLBCL).1“Too many patients with diffuse large B-cell lymphoma see their cancer relapse or progress after initial treatment. This highlights the need to improve on a standard-of-care that has remained unchanged for the last two decades,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer an d Head of Global Product Development. “These updated POLARIX data indicate the potential benefits that this Polivy based-regimen could bring to people living wit...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news